1. Home
  2. CINT vs FULC Comparison

CINT vs FULC Comparison

Compare CINT & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CI&T Inc

CINT

CI&T Inc

HOLD

Current Price

$4.71

Market Cap

646.9M

Sector

Technology

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$7.95

Market Cap

535.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CINT
FULC
Founded
1995
2015
Country
Brazil
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
646.9M
535.5M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
CINT
FULC
Price
$4.71
$7.95
Analyst Decision
Strong Buy
Buy
Analyst Count
6
8
Target Price
$7.35
$16.38
AVG Volume (30 Days)
68.1K
912.5K
Earning Date
05-12-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.69
N/A
Revenue Next Year
$11.28
N/A
P/E Ratio
$17.94
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.98
$3.39
52 Week High
$6.71
$15.74

Technical Indicators

Market Signals
Indicator
CINT
FULC
Relative Strength Index (RSI) 42.68 50.77
Support Level $4.53 $6.35
Resistance Level $5.02 $8.20
Average True Range (ATR) 0.22 0.52
MACD -0.01 0.13
Stochastic Oscillator 33.33 73.29

Price Performance

Historical Comparison
CINT
FULC

About CINT CI&T Inc

CI&T Inc operates as a partner in tech-integrated business solutions, helping organizations address complex challenges by integrating business approach, technology, and artificial intelligence into a single, coherent operating model. It is mainly engaged in the development of customizable software through the implementation of software solutions, including machine learning, artificial intelligence, data analytics, cloud migration and mobility technologies. The company provides technology services to various industry verticals, including Financial Services, Consumer Goods, Technology and Communications, Retail and Industrial Goods, Life Sciences, among others. The majority of the revenue is derived from providing technology services. Geographically, maximum revenue is derived from Brazil.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: